Summary
Two studies have been done to establish recommendations for dosage and dose adjustment in the treatment of deep vein thrombosis (DVT) with low molecular weight heparin (LMWH). In the first, 56 patients were randomized in a double blind study to be treated either with unfractionated heparin (UFH) or LMWH s. c. every 12 h. Initial doses were given according to age and sex, disregarding bodyweight, and the dose was then adjusted when the peak plasma heparin concentration fell outside the desired range of 0.5–0.8 anti-FXa U/ml.
There were fewer dose adjustments in the LMWH group. The correlation between injected dose (U/kg bodyweight) and the heparin concentration was higher in the LMWH group (r=0.59) than in the UFH group (r=0.38). The results suggest that, in order to obtain the desired heparin concentration, the initial dose of LMWH should be about 100 U/kg bodyweight every 12 h.
In the second, open study, this dosage plan was followed in 15 patients. The peak heparin concentration on Day 2 ranged from 0.40 to 0.75 anti-FXa U/ml and adjustment was only required in 3 patients. Day to day variation in peak heparin activity in the individual patient varied little (CV 11–22%), and there was no accumulation.
The results indicate that plasma heparin concentration is more predictable using LMWH than UFH, and they point to definite advantages in the use of LMWH in a bodyweight adjusted dosage.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Holmer E, Kurachi K, Söderström G (1981) The molecular-weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xia, Factor XIIa and kallikrein by antithrombin. Biochem J 193: 395–400
Anderson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderström G (1979) Molecular weight dependency of the heparin potentiation of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 15: 531–541
Thunberg L, Lindahl U, Tengblad N, Laurent TC, Jackson CM (1979) On the molecular-weight-dependency of the anticoagulant activity of heparin. Biochem J 181: 241–243
Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Söderström G, Andersson L-O (1980) Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 18: 861–869
Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J (1984) A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 35: 613–625
Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M (1982) The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59: 1239–1245
Carter CJ, Kelton JG, Hirsh J, Gent M (1981) Relationship between antithrombotic and anticoagulant effect of low molecular weight heparin. Thromb Res 21: 169–174
Levine MN, Hirsh J (1988) An overview of clinical trials of low molecular weight heparin fractions. Acta Chir Scand 154 [Suppl 543]: 73–79
Kehr A, Heilmann JJ, Barbier P (1988) Prevention of postoperative thromboembolism in orthopedic surgery. Therapie 43: 193–198
Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) Prospective double-blind comparison between Fragmin and conventional low-dose heparin: Thromboprophylactic effect and bleeding complications. Haemostasis 16 [Suppl 2]: 11–18
Kakkar VV (1984) Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction. Nouv Rev Fr Hematol 26: 277–282
Planes A, Vochell N (1986) Enoxaparin LMW heparin: Its use in prevention of DVT following total hip replacement. Haemostasis 16: 152–158
ten Cate H, Henny CP, ten Cate JW, Buller H, Mooy M, Surachno S, Wilmink J (1985) Anticoagulant effect of a low molecular weight heparinoid (ORG 10172) in human volunteers and haemodialysis patients. Thromb Res 38: 211–222
Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR (1986) On the evaluation of heparin and low molecular weight heparin in haemodialysis of chronic renal failure. Haemostasis 16 [Suppl 2]: 38–47
Schrader J, Kandt M, Zurcher C, Kostering H, Scheler F (1986) Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 16 [Suppl 2]: 48–58
Bratt G, Tornbohm E, Granqvist S, Aberg W, Lochner D (1985) A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 54: 813–817
Holm HA, Ly B, Handeland G, Abildgaard U, Arnesen KE, Gottchalk P, Hoegh V (1986) Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 16 [Suppl 2]: 30–37
Lochner D, Bratt G, Tornbohm E, Aberg W, Granqvist S (1986) Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 16 [Suppl 2]: 25–29
Bara L, Samama M (1988) Pharmacokinetics of low molecular weight heparins. Acta Chir Scand [Suppl 543]: 65–72
Bratt G, Toernbohm E, Lochner D, Bergstroem K (1985) A human pharmacological study comparing conventional heparin and low molecular weight heparin fragment. Thromb Haemostasis 53: 208–211
Bergqvist D, Hedner U, Sjoerin E, Holmer E (1983) Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 32: 381–391
Arnesen KE, Handeland G, Abildgaard U (1987) What is the optimal dosage of LMW heparin in the SC treatment of deep venous thrombosis? Thromb Haemost 58: 214
Handeland GF (1986) Simplified chromogenic substrate assay for low molecular weight heparin. Thromb Res 42: 105–108
Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III. Thromb Res 10: 399–410
Rabinov K, Paulin S (1972) Roentgen diagnosis of venous thrombosis in the leg. Archs Surg 104: 134–144
Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Algazy KM (1977) Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 84: 1018–1029
Holm HA, Abildgaard U, Kalvenes S, Andersen N, Anker E, Arnesen KE, Blinkom D, Drivenes A (1984) The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays. Acta Med Scand 216: 287–293
Holm HA, Finnanger B, Hartmann A, L. rum F, Lohren O, Ruud TE, Stray N, Wolland T (1984) Heparin treatment of dep venous thrombosis in 280 patients: Symptoms related to dosage. Acta Med Scand 215: 47–53
Bara G, Billaud E, Gramond G, Kher A, Samama M (1985) Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 39: 631–636
Morabia A (1986) Heparin doses and major bleedings. The Lancet I: 1278–1279
Holm HA, Abildgaard U, Kalvenes S (1985) Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 53: 278–281
Abildgaard U (1989) Monitoring heparin treatment. In: Lane DA, Lindal U (ed) Heparin, chemical and biological properties, clinical applications. Arnold, London, pp 495–515
Albada J, Nieuwenhuis HK, Sixma JJ (1989) Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Circulation 80: 935–940
Huet Y, Gouault-Heilmann M (1986) Low molecular weight heparin fraction PK 10169: A new therapeutic means for anticoagulant therapy? Haemostasis 16: 165–172
Hull RD, Raskob G, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D (1986) Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315: 1109–1114
Talstad I (1985) Heparin therapy adjusted by bodyweight. Am J Clin Pathol 83: 378–385
Lochner D, Bratt G, Tornebohm E, Åberg W (1986) Pharmacokinetics of intravenous and subcutaneously administered Fragmin in Healthy volunteers. Haemostasis 16 [Suppl 2]: 8–10
Dawes J, Bara L, Billaud E, Samama M (1986) Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 16: 116–122
Rowland M, Tozer TN (1980) Clinical Pharmacokinetics, Concepts and Applications. Lea and Febiger, Philadelphia, p 20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Handeland, G.F., Abildgaard, U., Holm, H.A. et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39, 107–112 (1990). https://doi.org/10.1007/BF00280041
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280041